Drug Profile
Dermatan sulfate - Sanofi-Synthelabo
Alternative Names: IC 1729Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antithrombotics; Glycosaminoglycans; Small molecules
- Mechanism of Action Glycosaminoglycan stimulants; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 14 Mar 2000 No-Development-Reported for Thrombosis in France (Injection)
- 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
- 18 Mar 1997 Preclinical development for Thrombosis in France (Parenteral)